Source: https://astrinbio.com/faq
Language: en

# Key questions in cancer detection and the **future of proteomics.**

## When and how does cancer spread?

Cancer doesn't always follow a linear path. Emerging research shows that tumor cells can enter the bloodstream well before a primary tumor is visible via a process known as early dissemination. Astrin's work, and others', supports this evolving understanding. These early disseminated tumor cells (DTCs) express unique proteins that can be detected in blood as early as stage 0 ([Klein et al., *Nature* 2016](https://www.nature.com/articles/nature20785)).

## How does AI enhance the field of proteomics? What is deep proteomics?

Each milliliter of blood contains billions of cells which produce proteins as signals for immune activation, tissue repair, or early malignancy. Sifting through the complex signals in the blood to detect early signs of cancer or identify treatment targets can be greatly facilitated by specialized AI algorithms. Astrin uses AI and deep spectral analysis to decode proteomic patterns found across >9,000 proteins from background noise ([Drake et al., *IDBW 2025*](https://astrinbio.com/files/2025-ibdw-poster.pdf)). Our AI enables us to detect cancer when signals are sparse, identify druggable protein targets, and even classify rare disseminated and circulating tumor cells based on their morphological features.

## What are the challenges with blood-based early cancer detection?

Early-stage tumors often shed very little DNA or structural material, making them difficult to detect with conventional liquid biopsy methods ([Bredno et al., *PLOS* 2021](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0256436)). At the same time, plasma contains highly abundant proteins like albumin and immunoglobulins, which mask more informative signals. Astrin addresses this challenge by focusing on identifying proteins of low abundance — where regulatory and cancer-associated proteins reside. This deeper resolution helps reveal what most blood tests miss: the earliest molecular signals of cancer development.

## Is proteomics new in cancer diagnostics?

Proteomics is not new — the first cancer-associated protein biomarkers, Bence-Jones proteins, were discovered in 1848 for multiple myeloma ([Bence Jones 1848](https://royalsocietypublishing.org/doi/10.1098/rstl.1848.0003)). However, until recently, the field lacked the tools to make proteomics clinically useful in large patient populations. In the past five years, advances in biochemistry, spectral signal processing, and AI have made it possible to measure thousands of proteins with high precision and reproducibility from a single blood sample. Astrin is among the first platforms to bring deep proteomics into clinical-grade cancer diagnostics, enabling early detection from blood with unmatched depth and biological resolution.

## Is proteomics better than genomics?

Not better, just different. Genomic tests reveal gene mutations that could cause cancer, but early-stage tumors may not release enough DNA into the bloodstream for detection. Proteins reflect real-time changes in immune activation, cell signaling, and tissue response — giving proteomics a time-sensitive edge for both early detection and treatment guidance. **Genomics shows what could happen. Proteomics shows what is actually happening.**

## What types of cancer are suited to proteome-guided diagnostics?

Deep proteomics is especially valuable in cancers that are hard to detect early, difficult to biopsy, or slow to release ctDNA into the bloodstream ([Bettegowda et al., *Sci. Trans. Med.* 2014](https://pmc.ncbi.nlm.nih.gov/articles/PMC4017867/)). These include breast cancer (particularly in women with dense breast tissue), prostate cancer, and other major cancers where early detection and treatment guidance remain major challenges ([Drake et al., *Endocrinology* 2024](https://academic.oup.com/endo/article/165/4/bqae022/7608821)).

## How effective are current breast cancer screening tools for women with dense breasts?

Nearly 50% of women over age 40 have dense breast tissue, which makes it hard for mammograms to detect cancer. Younger women are more likely to have dense breast tissue. Dense tissue is a stronger risk factor than family history for developing breast cancer ([Engmann et al., *JAMA* 2017](https://jamanetwork.com/journals/jamaoncology/fullarticle/2599991)). In women with dense tissue, even advanced 3D mammography has limited sensitivity — as low as 30–40% in early-stage cancers ([Comstock et al., *JAMA* 2020](https://jamanetwork.com/journals/jama/fullarticle/2761645)). This gap motivated Astrin to develop **Certitude**, a blood-based screening test designed for women with dense breast tissue, offering a more accurate and less invasive option for early detection.

## How often should women get screened for breast cancer?

The **USPSTF** recommends mammograms every two years for women aged 40 to 74. New research suggests that annual screening may improve survival, especially for women over 40. A recent study ([Zuley et al., *JCO* 2024](https://ascopubs.org/doi/10.1200/JCO.24.00285)) found that women screened annually had better outcomes, though this also increases false positives and unnecessary biopsies. These findings underscore the need for improved screening tools. Astrin’s blood-based test aims to detect cancer early while reducing false positives.

## What are dense breasts?

Breast density describes the ratio of connective to fatty tissue. It can’t be determined by touch — only a radiologist can assess it. Almost [half of women](https://pmc.ncbi.nlm.nih.gov/articles/PMC4200066/) have dense breasts.

## What does it mean to have dense breasts?

Having dense breasts increases the risk of [developing cancer up to 4–5×](https://www.sbi-online.org/news/breast-density-and-supplemental-screening#:~:text=Density%20and%20Breast%20Cancer%20Risk\&text=Women%20in%20the%20extreme%20density,to%20the%20Tyrer%2DCuzick%20model.) and mammograms miss about [40–50% of cancers in dense tissue](https://pmc.ncbi.nlm.nih.gov/articles/PMC9140155/) due to masking effects.

## A federal mandate about breast density was made last year. What is it and why was it put in place?

All women undergoing mammography [must be informed of their breast density](https://www.uclahealth.org/news/release/new-federal-mandate-breast-density-experts-provide-essential). There are four categories of breast density:

1. Almost entirely fatty
2. Scattered areas of fibroglandular density
3. Heterogeneously dense
4. Extremely dense

Categories **1–2** are *not dense*, while **3–4** are *dense*. The mandate ensures women are aware of their density category and what it means for their screening plan.

## How does Certitude look for cancer?

When cancer cells form, they release proteins into the plasma of the bloodstream. Historically, finding these specific proteins has been difficult due to the abundance of other proteins. **Certitude Breast** filters out normal proteins and uses AI to identify abnormal ones — detecting signals of cancer at its earliest stages.

## Who can take the test?

All women eligible for mammograms, those at high risk, or those referred by their provider can take the test. The Certitude Blood Test is especially valuable for women with dense breasts whose cancers may not appear on traditional imaging. Use of the Certitude Blood Test is not recommended in individuals who have gone or are undergoing active cancer treatment. The Certitude Blood Test should be used in addition to healthcare provider recommended screening tests.

## How accurate is the test?

In 1,214 women, Certitude Blood Test achieved **92% sensitivity** and **92% specificity** in detecting breast cancer with high sensitivity even at early stages. False positive and false negative results do occur.

## How is the test administered?

**Certitude** is a blood-based test obtained via a standard blood draw and analyzed in a lab. The goal is to soon make it available as a home-based test where patients can collect and send samples themselves.

## When will the test be broadly available?

Astrin aims to launch **Certitude** in select markets in **early 2026**, followed by a nationwide rollout in the **second half of 2026**.

## Contact

Hours of operation:
